Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Eli Lilly and tirzepatide
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the FDA said in a recent court filing.
1h
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
11h
on MSN
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...
8h
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...
1h
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
1d
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
1d
on MSN
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
FierceBiotech
21h
Eli Lilly expands innovation reach with another global Gateway Lab, this time in China
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
STAT
5d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
1d
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
1d
on MSN
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...
STAT
5h
Pharmalittle: We’re reading about using Lilly obesity drug to reduce sick days, Sanofi workers striking, and more
The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Mounjaro
Zepbound
Artificial intelligence
United Kingdom
Omvoh
Feedback